Эртапенем — представитель новой группы карбапенемов | КМАХ

Эртапенем — представитель новой группы карбапенемов

Клиническая Микробиология и Антимикробная Химиотерапия. 2009; 11(1):40-55

​ Козлов Р.С., Никулин А.А.
карбапенемы эртапенем антимикробная активность резистентность фармакокинетика
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2009; 11(1):40-55

Аннотация

Карбапенемы относятся к классу β-лактамных антибиотиков с исключительно широким спектром антимикробной активности, хорошими фармакокинетическими параметрами и низкой токсичностью. Такие препараты, как имипенем и меропенем, уже длительное время успешно применяются в клинической практике при лечении тяжёлых нозокомиальных инфекций. Появившийся в 2002 г. эртапенем представляет новую группу карбапенемов. Он отличается от вышеназванных препаратов как спектром антимикробной активности, включающим активность в отношении БЛРС и AmpC-продуцирующих микроорганизмов, что меняет представление о карбапенемах как о препаратах резерва, так и улучшенными фармако­кинетическими показателями, что позволяет назначать его один раз в сутки. В статье представлены фармакологические, микробиологические и клинические данные об эртапенеме.

  • 1. Norrby S.R. Carbapenems. Med Clin North Am 1995; 79:745-59.
  • 2. Balfour J.A., Bryson H.M., and Brogden R.N. 1996. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 51:99-136.
  • 3. Moellering R.C., Eliopoulos G.M., Sentochnik D.E. The carbapenems: new broad spectrum beta-lactam antibiotics. J.Antimicrob.Chemother. 1989;24 (Suppl A):1-7.
  • 4. Bonfiglio G., Russo G., and Nicoletti G. Recent developments in carbapenems. Expert Opin Investig Drugs 2002; 11:529-44.
  • 5. Shah P.M. and Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52:538-42.
  • 6. Ayalew, K., Nambiar S., Yasinskaya Y., and Jantausch B.A. Carbapenems in pediatrics. Ther Drug Monit 2003; 25:593-99.
  • 7. Norrby S.R. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother 2000; 45:5-7.
  • 8. Norrby S.R. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996;15:87-90.
  • 9. Edwards J.R. and Turner P.J. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995; (Suppl) 96:5-10.
  • 10. Edwards J.R. and Betts M.J. Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement? J Antimicrob Chemother 2000 45:1-4.
  • 11. Edwards S.J., Emmas C.E., and Campbell H.E. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005; 21:785-94.
  • 12. Edwards S.J., Campbell H.E., and Plumb J.M. Costutility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006; 7:72-8.
  • 13. Cunha B.A. Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (Barc.) 2002;38:195-213.
  • 14. Curran M., Simpson D., and Perry C. Ertapenem: a review of its use in the management of bacterial infections. Drugs 2003; 63:1855-78.
  • 15. Hammond M.L. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother 2004; (Suppl 2):ii7-ii9.
  • 16. Goldstein E.J. and Snydman D.R. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; (Suppl 2):ii29-ii36.
  • 17. Fukasawa M., Sumita Y., Harabe E.T., et al. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Ag Chemother 1992; 36:1577-79.
  • 18. Mouton J.W., Touzw D.J., Horrevorts A.M., and Vinks A.A. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39:185-201.
  • 19. Livermore D.M., Sefton A.M., and Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52:331-44.
  • 20. Kohler J., Dorso K. L., Young K., et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Ag Chemother 1999; 43:1170-76.
  • 21. Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs 2001; 10:1157-66.
  • 22. Coudron P.E., Hanson N.D., and Climo M.W. Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC betalactamases. J Clin Microbiol 2003; 41:772-7.
  • 23. Kohler J.Y., Painter E., Inumerable A., and Silver L. Ertapenem resistance selection in Pseudomonas aeruginosa. Proceedings of the 41stIntersc Conference on Antimicrobial Agents and Chemotherapy. 2001.
  • 24. Friedland H.S, Stinson L, and Gallagher D. Pseudomonas aeruginosa resistance to imipenem (IMI), ertapenem (ETP) and other antibiotics: results of a multicenter ICU study. Proceedings of the41st Intersc Conference on Antimicrobial Agents and Chemotherapy. 2001. Abstr E805.
  • 25. Jacoby G.A., Mills D.M., and Chow N. Role of betalactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3203-6.
  • 26. Wexler H.M. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004;53 (Suppl 2):ii11-ii21.
  • 27. Jacoby G., Han P., and Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother 1997;41:1830-1.
  • 28. Livermore D.M., Oakton K. J., Carter M. W., and Warner M. Activity of ertapenem (MK-0826) versus Entero­bacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 2001; 45:2831-7.
  • 29. Friedland I., Mixson L.A., Majumdar A., Motyl M., and Woods G.L. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. J Chemother 2002; 14:483-91.
  • 30. Fuchs P.C., Barry A.L., and Brown S. D. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother 1999; 43:703-6.
  • 31. Fuchs P.C., Barry A.L., and Brown S.D. Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria. J Antimicrob Chemother 2001; 48:23-8.
  • 32. Fuchs, P.C., Barry A.L., and Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45:1915-8.
  • 33. Ge Y., Wikler M.A., Sahm D.F., Blosser-Middleton R.S., and Karlowsky J. A. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004; 48:1384-96.
  • 34. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K., and Fernandez H. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J Antimicrob Chemother 2001; 48:641-51.
  • 35. Hicks P.S., Pelak B., Woods G.L., Bartizal K. F., and Motyl M. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin Microbiol Infect 2002; 8:753-7.
  • 36. Hilliard N.J., Johnson C.N., Armstrong S.H., Quarles S., and Waites K. B. In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 2002; 20:136-40.
  • 37. Jones R.N. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J Chemother 2001; 13:363-76.
  • 38. Jones R.N., Huynh H.K., Biedenbach D.J., Fritsche T.R., and Sader H. S. Doripenem (S-4661), a novel carba­penem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54:144-54.
  • 39. Livermore D.M., Carter M.W., Bagel S., et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. AntimicrobAgents Chemother 2001; 45:1860-67.
  • 40. Pankuch, G.A., Davies T.A., Jacobs M.R., and Appelbaum P.C. Antipneumococcal activity of ertapenem (MK0826) compared to those of other agents. Antimicrob Agents Chemother 2002; 46:42-6.
  • 41. Pelak B.A., Citron D.M., Motyl M., Goldstein E.J., Woods G.L., and Teppler H. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J Antimicrob Chemother 2002; 50:735-41.
  • 42. Pelak B.A., Woods G. L., Teppler H., Friedland I., Bartizal K. and Motyl M. Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J Chemother 2002; 14:227-3.
  • 43. Pelak B.A., Bartizal K., Woods G. L., Gesser R. M., and Motyl M. Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections. Diagn Microbiol Infect Dis 2002; 43:129-33.
  • 44. Reynolds R., Potz N., Colman M., Williams A., Livermore D., and MacGowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53:1018-32.
  • 45. Rhomberg P.R. and Jones R.N. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis 2003; 47:365-72.
  • 46. Rolston K.V., LeBlanc B.M., Streeter H., and Ho D.H. In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagn Microbiol Infect Dis 200;. 43:219- 23.
  • 47. Thomson K.S. and Moland E.S. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J AntimicrobChemother 2004; 54:557-62.
  • 48. Watanabe A., Tokue Y., Takahashi H., et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001; 7:267-71.
  • 49. Alhambra A., Cuadros J.A., Cacho J., Gomez-Garces J.L., and Alos J.I. In vitro susceptibility of recent antibioticresistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004; 53:1090-4.
  • 50. Livermore D.M., Alexander S., Marsden B., et al. Activity of ertapenem against Neisseria gonorrhoeae. J Antimicrob Chemother 2004; 54:280-1.
  • 51. Rennie R.P., Jones R.N., and Mutnick A. H. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45:287-93.
  • 52. Aldridge K.E. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis 2002; 44:181-6.
  • 53. Betriu C., Sanchez A., Palau M.L., Gomez M., and Picazo J.J. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains. Antimicrob Agents Chemother 2001; 45:2372-4.
  • 54. Goldstein E.J., Citron D.M., Vreni M. C., Warren Y., and Tyrrell K. L. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2000; 44:2389-94.
  • 55. Goldstein, E.J., Citron D. M., Merriam C. V., Warren Y., Tyrrell K. L., and Gesser R. M. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillintazobactam. Clin Infect Dis 2002; 35:S119-S125.
  • 56. Goldstein, E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., and Fernandez H. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob Agents Chemother 2002; 46:1136-40.
  • 57. Hoellman D.B., Kelly L.M., Jacobs M.R., and Appelbaum P.C. In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds. Clin Microbiol Infect 2002; 8:814-22.
  • 58. Hoellman D.B., Kelly L.M., Credito K., Anthony L., Ednie L.M., Jacobs M.R., and Appelbaum P. C. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother 2002; 46:220-4.
  • 59. Wexler H.M., Molitoris D., and Finegold S.M. In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria. Antimicrob Agents Chemother 2000; 44:2222-4.
  • 60. Majumdar A.K., Musson D.G., Birk K.L., et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46:3506-11.
  • 61. Musson D.G., Majumdar A., Birk K., et al. Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother 2003; 47:1732-5.
  • 62. Musson, D.G., Majumdar A., Holland S., et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother 2004; 48:521-4.
  • 63. Nix D.E., Majumdar A.K., and DiNubile M.J. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 (Suppl 2):ii23-ii28.
  • 64. Sundelof J.G., Hajdu R., Gill C.J., Thompson R., Rosen H., and Kropp H. Pharmacokinetics of L-749,345, a longacting carbapenem antibiotic, in primates. Antimicrob Agents Chemother 1997; 41:1743-8.
  • 65. Laethem T., De L., McCrea I.J., et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 2003; 47:1439-42.
  • 66. Cottagnoud P., Pfister M., Cottagnoud M., Acosta F., and Tauber M. G. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2003; 47:1943-7.
  • 67. Invanz® product monograph. MerckFrosst Canada & Company, Quebec,Canada (2003) . 2009.
  • 68. Wong B.K., Sahly Y., Mistry G., et al. Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica 2004; 34:379-89.
  • 69. Pletz M.W., Rau M., Bulitta J., et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48:3765-72.
  • 70. Xuan D., Banevicius M., Capitano B., Kim M.K., Nightingale C., and Nicolau D. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob Agents Chemother 2002; 46:2990-5.
  • 71. Odenholt I., Lowdin E., and Cars O. In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1998; 42:2365-70.
  • 72. Buckley M.M., Brogden R.N., Barradell L.B., and Goa K.L. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992; 44:408-44.
  • 73. Bush L.M., Calmon J., and Johnson C.C. Newer penicillins and beta-lactamase inhibitors. Infect Dis Clin North Am 1995; 9:653-86.
  • 74. Chiu L.M., Menhinick A.M., Johnson P.W., and Amsden G.W. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002; 50:1075-9.
  • 75. Christ W. Pharmacological properties of cephalosporins. Infection 1991; 19 (Suppl 5):S244-S252.
  • 76. Moon Y.S., Chung K.C., and Gill M.A. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 1997; 24 (Suppl 2):S249-S255.
  • 77. Sorgel F. and Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993; 31 (Suppl A):39-60.
  • 78. Solomkin J.S., Yellin A. E., Rotstein O. D., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237:235-45.
  • 79. Yellin, A.E., Hassett J.M., Fernandez A., et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intraabdominal infections in adults. Int J Antimicrob Agents 2002; 20:165-73.
  • 80. Graham D.R., Lucasti C., Malafaia O., et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34:1460-8.
  • 81. Gesser R.M., McCarroll K.A., and Woods G.L. Effi­cacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam. Int J Antimicrob Agents 2004; 23:235-9.
  • 82. Gesser R.M., McCarroll K.A., and Woods G.L. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J.Infect. 48:32-38.
  • 83. Lipsky B.A., Armstrong D.G., Citron D.M., Tice A.D., Morgenstern D.E., and Abramson M.A.. 2005. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2004; 366:1695-703.
  • 84. Roy S., Higareda I., E. ngel-Muller, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003; 11:27-37.
  • 85. Jimenez-Cruz F., Jasovich A., Cajigas J., et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002; 60:16-22.
  • 86. Tomera K.M., Burdmann E. A., Reyna O. G., et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002; 46:2895-900.
  • 87. Wells W.G., Woods G.L., Jiang Q., and Gesser R.M. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, doubleblind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004; 53 (Suppl 2):ii67-ii74.
  • 88. Ortiz-Ruiz G., Caballero-Lopez J., Friedland I.R., Woods G.L., and Carides A. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002; 34:1076-83.
  • 89. Vetter N., Cambronero-Hernandez E., Rohlf J., et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with communityacquired pneumonia. Clin Ther 2002; 24:1770-85.
  • 90. Ortiz-Ruiz G., Vetter N., Isaacs R., Carides A., Woods G.L., and Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53 (Suppl 2):ii59-ii66.
  • 91. Woods G.L., Isaacs R.D., McCarroll K. A., and Friedland I.R. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 2003; 51:1526-32.
  • 92. Teppler H., McCarroll K., Gesser R.M., and Woods G.L. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillintazobactam. Surg Infect (Larchmt.) 2002; 3:337-49.
  • 93. Solomkin J., Teppler H., Graham D.R., et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J Antimicrob Chemother 2004; 53 (Suppl 2):ii51-ii57.
  • 94. Gesser R.M., McCarroll K., Teppler H., and Woods G.L. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 2003; 51:1253-60.
  • 95. Munoz L.S., Hovsepian M., and Snydman D.R. Ertapenem for the treatment of extended spectrum β-lactamase (ESBL) producing organisms. Proceedings of the 44thIntersc Conference on Antimicrobial Agents Chemotherapy.Washington, DC, WA,USA, 30 October2 November 2004(Abstract K-1591). 2004.
  • 96. Teppler H., Gesser R.M., Friedland I. R., et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53 (Suppl 2):ii75-ii81.
  • 97. Legua P., Lema J., Moll J., Jiang Q., Woods G., and Friedland I. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin Ther 2002; 24:434-44.
  • 98. Hotchkies L., Grima D.T., and Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clin Ther 1996; 18:716-25.
  • 99. Tice A.D. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2004; 53 (Suppl 2):ii83-ii86.
  • 100. Tellado J., Woods G.L., Gesser R., McCarroll K., and Teppler H. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intraabdominal, complicated skin and skin structure, and acute pelvic infections. Surg Infect (Larchmt.) 2002; 3:303-14.
  • 101. Bernard L., El H., Pron B., et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001; 26:445-51.
  • 102. Wai A.O., Frighetto L., Marra C.A., Chan E., and Jewesson P.J. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics 2000; 18:451-7.
  • 103. Available from http://www.regmed.ru/.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились